Jade Biosciences, Inc.
NASDAQJBIO heads into its June 9 earnings print with analysts raising targets at an accelerating pace — and the stock ignoring every word of it. The Street's enthusiasm has been unambiguous this week. Three separate target increases arrived in two days. BTIG's Julian Harrison nearly doubled his target on June 1, moving from $39 to $74 while keeping his Buy rating. Wedbush followed on…
JBIO utilization hits 100%, matching its 52-week peak, as short interest surges 33% in one day to 9.2% of float.
Snapshot as of 25 Jun 2026
JBIO heads into its June 9 earnings print with analysts raising targets at an accelerating pace — and the stock ignoring every word of it. The Street's enthusiasm has been unambiguous this week. Three separate target…
JBIO enters its June 9 earnings window with shorts methodically rebuilding, analysts still constructive but increasingly alone in their optimism, and a stock that has shed 20% in a month while trading at $21.04. Short…
Jade Biosciences heads into the final stretch before its June earnings with the Street firmly behind the stock — even as the price pulls back sharply from recent highs. The timing is striking. Guggenheim and Wedbush…
JBIO heads into its May 14 Q1 results with a wall of analyst upgrades at its back — and short sellers who spent April building positions now quietly retreating. The analyst story is unambiguous. Both Guggenheim and…
JBIO short sellers made an aggressive move on May 7. Short interest jumped 33% in a single session to 9.2% of free float. The lending pool is now completely exhausted — availability has dropped to 0%, matching the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JBIO — free to start on ORTEX.
Sign up for free →Open JBIO on ORTEX